| Aurobindo Pharma Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 524804 |
NSE Symbol : AUROPHARMA |
P/E(TTM) : 47.17 |
|
ISIN Demat : INE406A01037 |
Div & Yield% : 0.29 |
EPS(TTM) : 32.62 |
|
Book Value(₹) : 336.60 |
Market Cap(₹Cr) : 90,161.30 |
Face Value(₹) : 1.00 |
| Particulars | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|
| INCOME : | |||||
| Sales Turnover | 10,645.64 | 8,457.00 | 11,287.14 | 15,823.68 | 13,370.77 |
| Excise Duty | - | - | - | - | - |
| Net Sales | 10,645.64 | 8,457.00 | 11,287.14 | 15,823.68 | 13,370.77 |
| Other Income | 670.10 | 443.92 | 670.99 | 589.86 | 388.79 |
| Stock Adjustments | 116.23 | 263.95 | -45.51 | -2.99 | 238.67 |
| Total Income | 11,431.97 | 9,164.87 | 11,912.62 | 16,410.55 | 13,998.23 |
| EXPENDITURE : | |||||
| Raw Materials | 5,964.48 | 4,755.95 | 5,800.74 | 7,241.83 | 6,819.85 |
| Power and Fuel Cost | 191.58 | 167.86 | 477.99 | 512.34 | 526.31 |
| Other Manufacturing Expenses | 414.51 | 328.42 | 705.68 | 925.86 | 814.44 |
| Selling and Administration Expenses | 822.21 | 939.38 | 1,009.36 | 1,069.84 | 938.36 |
| Miscellaneous Expenses | 164.49 | 148.96 | 249.13 | 215.57 | 235.47 |
| Employee Benefit Expenses | 980.56 | 890.53 | 1,600.04 | 1,735.42 | 1,577.14 |
| Less: Preoperative Expenditure | - | - | - | - | - |
| Total Expenses | - | - | - | - | - |
| Operating Profit | 2,894.14 | 1,933.77 | 2,069.68 | 4,709.69 | 3,086.66 |
| Interest | 182.60 | 74.58 | 16.94 | 28.68 | 243.28 |
| Gross Profit | 2,711.54 | 1,859.19 | 2,052.74 | 4,681.01 | 2,843.38 |
| Depreciation | 254.58 | 243.26 | 415.26 | 488.00 | 473.33 |
| Profit Before Tax | 2,456.96 | 1,615.93 | 1,637.48 | 4,193.01 | 2,370.05 |
| Current Tax | 598.08 | 412.16 | 379.70 | 1,043.34 | 492.28 |
| Fringe Benefit tax | - | - | - | - | - |
| Deferred Tax | -95.26 | -23.34 | -196.93 | 36.76 | 0.89 |
| Reported Net Profit | 1,954.14 | 1,227.11 | 1,454.71 | 3,112.91 | 1,876.88 |
| Extraordinary Items | 1.17 | 9.94 | -81.27 | -0.13 | -1.90 |
| Adjusted Net Profit | 1,952.97 | 1,217.17 | 1,535.98 | 3,113.04 | 1,878.78 |
| Adjustment below Net Profit | -1.69 | 8.28 | 1.69 | -6.42 | -44.88 |
| Profit/Loss Balance carried down | 16,660.08 | 15,864.14 | 14,671.41 | 11,799.30 | 10,143.08 |
| Statutory Appropriations | - | - | - | - | - |
| Appropriations | 263.66 | 439.45 | 263.67 | 234.38 | 175.78 |
| P & L Balance carried down | 18,348.87 | 16,660.08 | 15,864.14 | 14,671.41 | 11,799.30 |
| Dividend | 263.66 | 439.45 | - | - | - |
| Preference Dividend | - | - | - | - | - |
| Equity Dividend (%) | 450.00 | 750.00 | 900.00 | 400.00 | 300.00 |
| Dividend Per Share(Rs) | 4.50 | 7.50 | 9.00 | 4.00 | 3.00 |
| Earnings Per Share-Unit Curr | 33.35 | 20.94 | 24.83 | 53.13 | 32.03 |
| Earnings Per Share(Adj)-Unit Curr | 33.35 | 20.94 | 24.83 | 53.13 | 32.03 |
| Book Value | 336.62 | 307.80 | 292.15 | 271.80 | 222.78 |
| Book Value(Adj)-Unit Curr | 336.62 | 307.80 | 292.15 | 271.80 | 222.78 |